# Mereo BioPharma Group plc (MREO) — delisting/forced [announced]
Source: sec.gov · situation sit_f10e9ac2221bfc4b6ecc · public 9995625591540123732 · retrieved 2026-08-20T12:39:10.977Z

## Overview
Mereo BioPharma Group plc is a pharmaceutical company developing drug candidates; it is listed on The Nasdaq Capital Market under the ticker MREO.

Mereo BioPharma Group plc received a second notice from Nasdaq on August 18, 2026, confirming that the company has failed to maintain the minimum bid price of $1.00 per share required for continued listing on The Nasdaq Capital Market under Listing Rule 5550(a)(2). The company was initially provided 180 calendar days (until August 17, 2026) to regain compliance following a first notice on February 17, 2026. Nasdaq has now granted an additional 180 calendar day cure period extending to February 16, 2027. If the closing bid price of the company's American Depositary Shares reaches at least $1.00 per share for a minimum of 10 consecutive business days during this period, Nasdaq will provide written confirmation of compliance. If the company fails to regain compliance by February 16, 2027, Nasdaq will issue a delisting notice, after which the company may appeal to a Nasdaq Hearings Panel.

## Terms
- Counterparty: The Nasdaq Stock Market LLC · Price/share: $1

## Key dates
- Announced 2026-08-19 · Expiry 2027-02-16

## Timeline
- 2026-08-19 · 8-K (0001193125-26-356168): 8-K - Mereo BioPharma Group plc — *Mereo BioPharma Group plc is a pharmaceutical company developing drug candidates; it is listed on The Nasdaq Capital Market under the ticker MREO.* Mereo BioPharma Group plc received a second notice from Nasdaq on August 18, 2026, confirming that the company has failed to maintain the minimum bid price of $1.00 per share required for continued listing on The Nasdaq Capital Market under Listing Rule 5550(a)(2). The company was initially provided 180 calendar days (until August 17, 2026) to regain compliance following a first notice on February 17, 2026. Nasdaq has now granted an additional 180 calendar day cure period extending to February 16, 2027. If the closing bid price of the company's American Depositary Shares reaches at least $1.00 per share for a minimum of 10 consecutive business days during this period, Nasdaq will provide written confirmation of compliance. If the company fails to regain compliance by February 16, 2027, Nasdaq will issue a delisting notice, after which the company may appeal to a Nasdaq Hearings Panel.
  https://www.sec.gov/Archives/edgar/data/1719714/0001193125-26-356168.txt

## Citations
- 0001193125-26-356168 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526356168